173 completed. 173 Phase 1, 55 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 173 | Completed 173 |
| Phase 2 | 55 | Completed 55 |
Follow Heart Failure: new trials by email Literature Review of Heart Failure trials Research Report on Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants THRV-1268, Placebo - Heart Failure | Phase 1 | Completed | Thryv Therapeutics, Inc. | 16 | 2025-09-15 | 2026-01-14 |
| A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462 AZD5462 film-coated tablet, [14C]AZD5462 Solution for Infusion, [14C]AZD5462 Oral Solution - Heart Failure | Phase 1 | Completed | AstraZeneca | 8 | 2025-05-20 | 2025-07-04 |
| Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka HFrEF Polypill, Comparator Arm - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Washington University School of Medicine | 40 | 2025-02-15 | 2025-05-08 |
| A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects SHR-6934 injection, SHR-6934 placebo - Heart Failure | Phase 1 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 72 | 2025-01-06 | 2026-05-28 |
| A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin NNC0537-1482, Placebo - Healthy Volunteers, Heart Failure | Phase 1 | Completed | Novo Nordisk A/S | 31 | 2024-10-03 | 2026-06-22 |
| A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years Formulation 1, Formulation 2, Formulation 3 - Heart Failure | Phase 1 | Completed | Bayer | 19 | 2024-07-01 | 2024-10-08 |
| Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers SCP-111, Furosemide USP - Heart Failure, Fluid Overload | Phase 1 | Completed | scPharmaceuticals, Inc. | 21 | 2024-04-19 | 2026-03-30 |
| The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART) Anakinra - Heart Failure | Phase 1 | Completed | Virginia Commonwealth University | 4 | 2024-02-05 | 2026-09-04 |
| A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure mRNA-0184, Placebo - Chronic Heart Failure | Phase 1 | Completed | ModernaTX, Inc. | 48 | 2022-12-05 | 2025-03-17 |
| Effects of Triiodothyronine (T3) in Ischemic Heart Failure Thyroid hormone T3, Control Group - Heart Failure | Phase 1 | Completed | Emory University | 14 | 2022-12-02 | 2026-08-04 |
| ALLEVIATE-HF-HD Study ALV1System - Heart Failure | Phase 1 | Completed | Alleviant Medical, Inc. | 5 | 2022-06-30 | 2023-07-18 |
| Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 CRD-740, Itraconazole - Clinical Pharmacology, Pharmacokinetics | Phase 1 | Completed | Cardurion Pharmaceuticals, Inc. | 20 | 2022-06-27 | 2025-05-15 |
| Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults Rapamune - Heart Failure | Phase 1 | Completed | Mayo Clinic | 24 | 2022-05-24 | 2023-09-28 |
| Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) XXB750, Placebo - Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | Phase 1 | Completed | Novartis Pharmaceuticals | 27 | 2022-05-17 | 2025-09-30 |
| A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) HS-001 CS, HS-001-D needle, HS-001-D Adaptor - Heart Failure, Ischemic Heart Disease | Phase 1 / Phase 2 | Completed | Heartseed Inc. | 10 | 2022-04-19 | 2026-10-22 |
| A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803 PF-07265803 - Healthy | Phase 1 | Completed | Pfizer | 6 | 2022-03-31 | 2024-03-29 |
| A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately Vericiguat (BAY1021189) - Intervention A, Vericiguat (BAY1021189) - Intervention B, Vericiguat (BAY1021189) - Intervention C - Heart Failure, Children | Phase 1 | Completed | Bayer | 36 | 2021-10-12 | 2023-02-02 |
| Treating Heart Failure With hPSC-CMs hPSC-CM Therapy - Heart Failure | Phase 1 / Phase 2 | Completed | HELP Therapeutics Co., Ltd. | 20 | 2021-10-08 | 2025-08-22 |
| Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg - Hypertension, Heart Failure | Phase 1 | Completed | Pfizer | 72 | 2021-09-22 | 2024-07-12 |
| ALLEVIATE-HFrEF Study ALV1 System - Heart Failure | Phase 1 | Completed | Alleviant Medical, Inc. | 5 | 2021-08-10 | 2023-07-18 |
Showing 20 of 173. Sign in to see all of them.
Cardiomyopathies (11) · Heart Failure, Systolic (7) · Cardiovascular Diseases (6) · Myocardial Infarction (6) · Renal Insufficiency (6) · Cardiomyopathy, Dilated (5) · Hypertension (5) · Mitral Valve Insufficiency (5) · Heart Failure, Diastolic (4) · Breast Neoplasms (3) · Hypertension, Pulmonary (3) · Pulmonary Disease, Chronic Obstructive (3) · Atrial Fibrillation (2) · Cardio-Renal Syndrome (2)
Heart Diseases (171) · Cardiovascular Diseases (167) · Pathological Conditions, Signs and Symptoms (26) · Pathologic Processes (22) · Vascular Diseases (17) · Respiratory Tract Diseases (14) · Lung Diseases (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Kidney Diseases (8) · Myocardial Ischemia (7) · Chronic Disease (6)
Furosemide (7) · AZD9977 (5) · Natriuretic Peptide, Brain (5) · Sodium Chloride (4) · Interleukin 1 Receptor Antagonist Protein (3) · Triiodothyronine (3) · vericiguat (3) · Adrenergic beta-Antagonists (2) · Itraconazole (2) · Milrinone (2) · Moxifloxacin (2) · Mutagenesis, Insertional (2) · Saline Solution (2) · Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH (2) · Spironolactone (2)
Bristol-Myers Squibb (9) · Mayo Clinic (9) · AstraZeneca (8) · Bayer (7) · GlaxoSmithKline (4) · Alleviant Medical, Inc. (3) · Bial - Portela C S.A. (3) · Cytokinetics (3) · Nile Therapeutics (3) · University of Michigan (3) · University of Pennsylvania (3) · Viacor (3) · Virginia Commonwealth University (3) · Washington University School of Medicine (3) · Abramson Cancer Center at Penn Medicine (2)
United States (93) · United Kingdom (15) · Germany (14) · Japan (7) · Canada (5) · China (5) · Netherlands (4) · Poland (4) · Denmark (3) · Georgia (3) · India (3) · Australia (2) · Brazil (2) · Czechia (2) · Switzerland (2)
Horng H. Chen, M.D. (4) · Amit Patel, MD (2) · Andrew R Coggan, PhD (2) · Anne R Cappola, MD,ScM (2) · Bonnie Ky, MD, MSCE (2) · Horng H Chen, MD (2) · Jeffrey Testani, MD (2) · Linda R Peterson, MD (2) · Pablo Forte Soto, MD, MSc, PhD (2) · A. G. Kfoury, MD (1)
PMID 22936827, PMID 23031283, PMID 37804170, PMID 40899260, PMID 10618557, PMID 10723976, PMID 10843268, PMID 10999979, PMID 11176729, PMID 11561221, PMID 11705426, PMID 11755290, PMID 11832662, PMID 11911756, PMID 12016627, PMID 12140801, PMID 12140805, PMID 12151474, PMID 15704055, PMID 15739984, PMID 15795361, PMID 15812741, PMID 18553028, PMID 19327618, PMID 19679246, PMID 19958962, PMID 21422390, PMID 21492763, PMID 21709064, PMID 21856480, PMID 22088800, PMID 22438931, PMID 22651868, PMID 22965994, PMID 22968742, PMID 22980293, PMID 23099357, PMID 23122795, PMID 23362308, PMID 23592107, PMID 23633132, PMID 24065463, PMID 24107588, PMID 24444305, PMID 24627436, PMID 24801899, PMID 25037310, PMID 25187002, PMID 25212533, PMID 25262369
P01HL076611 (5), R01HL084155 (5), UL1RR024150 (4), 2005 (2), 2014 (2), 2016 (2), 2017 (2), 2019 (2), R61HL146390 (2), UL1TR000135 (2), 1KL2RR031989-01 (1), 2015 (1), 2023 (1), P01HL066941 (1), P01HL103455 (1)